Medical device maker Becton Dickinson’s CFO to depart; shares slide

Audio By Carbonatix

(Reuters) -Becton Dickinson said on Wednesday that its Chief Financial Officer Chris DelOrefice will depart the company, effective December 5, after four years at the medical device maker.

Shares of the company fell 5.8% to $176 in extended trading.

The company said it is conducting a search to identify a permanent successor and named insider Vitor Roque, senior vice president of finance, business units, as the interim CFO.

Roque will assume the role upon DelOrefice’s departure. DelOrefice informed the company of his intention to resign on October 9, to pursue a new professional opportunity, Becton said in a regulatory filing.

“Vitor brings extensive knowledge of the company having served in a broad range of finance leadership roles over his two decades at BD,” said CEO Tom Polen.

Becton also said it expects to report 2025 adjusted profit at or above the midpoint of its previous forecast range of $14.30 to $14.45 per share.

The medical device maker posted full-year preliminary revenue of approximately $21.8 billion, in line with analysts’ estimates.

It reported preliminary fourth-quarter revenue of about $5.9 billion, an increase of about 8.3% on a reported basis. Analysts expected a revenue of $5.91 billion, as per data compiled by LSEG.

Polen said the company continues “to navigate a dynamic macro environment that had a greater than anticipated impact this quarter,” specifically in areas such as pharmaceutical systems vaccines as well as biosciences academic and government research.

Life sciences firms have been flagging uncertainty related to the Trump administration’s proposed cuts to federal research grants.

(Reporting by Sneha S K in Bengaluru; Editing by Alan Barona)